ORYZON to Participate in Upcoming Events in February and March

About this update from Oryzon Genomics Sa

[{"type":"image","alt":"Oryzon Genomics, S.A.","displaySize":"","headline":null,"caption":"Oryzon Genomics, S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cNdaqSWVXmpOQnfrePXGFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2","width":182,"height":70}},"lazy":false},{"type":"text","content":"MADRID and CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events:","length":280,"tagName":"p"},{"type":"text","content":"Bio-Neuroscience 2026, February 24-27Location: Hotel Jakarta, Amsterdam","length":72,"tagName":"p"},{"type":"text","content":"SmallCap Event 20th Edition, March 17Location: Les Salons Hoche, Paris","length":71,"tagName":"p"},{"type":"text","content":"BIO-Europe Spring 2026, March 23-25Location: Feira Internacional de Lisboa (FIL), Lisbon","length":89,"tagName":"p"},{"type":"text","content":"LSX World Congress Europe, March 25-26Location: Lisbon Congress Centre, LisbonPresentation type: Panel DiscussionPresentation date and time: March 25, 14:00 GMT","length":163,"tagName":"p"},{"type":"text","content":"Oryzon management will be available for one-on-one meetings during the conferences.","length":83,"tagName":"p"},{"type":"text","content":"About OryzonFounded in 2000 and headquartered in Barcelona, Spain, Oryzon (ISIN: ES0167733015) is a clinical-stage biopharmaceutical company and a European leader in epigenetics, with a strong focus on personalized medicine for central nervous system (CNS) disorders and oncology. Oryzon’s team comprises highly experienced pharmaceutical professionals based in Barcelona, Boston, and New Jersey. The Company has an advanced clinical portfolio built around two LSD1 inhibitors: vafidemstat, its lead CNS program, which is Phase III–ready; and iadademstat, its oncology/hematology program, with several ongoing Phase I and II studies and outstanding preliminary results in first-line acute myeloid leukemia, including a 100% overall response rate (ORR) pr...

More updates from Oryzon Genomics Sa